Ben Stanger, MD, PhD

Gastroenterology
Accepting new patients
Sees patients age 18 and up
Penn Gastroenterology Radnor
Make an appointmentCall 610-902-1500
Penn Medicine Provider

About me

  • Director, Penn Pancreatic Cancer Research Center (PCRC)
  • Hanna Wise Professor in Cancer Research
  • Professor of Medicine in Cell and Developmental Biology

My education and training

  • Medical School: Harvard Medical School
  • Residency: University of California San Francisco
  • Fellowship: Massachusetts General Hospital

Spoken languages

English
English

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: On the medical staff, but does not have privileges to treat patients in the hospital.
Dr. Stanger is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

Research

Publications

Than MT, Stanger BZ Pancreatic ductal adenocarcinoma: the Everest of cancer biology , J Clin Invest, 135(14): 2025,e191936

Orlen MI, Vostrejs WP, Sor R, McDevitt JC, Kemp SB, Kim IK, Kramer AB, Tovbis Shifrin N, Markosyan N, Clendenin C, Singh M, Quintana E, Menard M, Vonderheide RH, Stanger BZ T-cell dependency of tumor regressions and complete responses with RAS(ON) multi-selective inhibition in preclinical models of PDAC , Cancer Discov, 15(8): 2025,1697-1716

Kahn BM, Ng RWS, Kim IK, Eskandarian C, Chen CO, Huang B, Lucas A, Li L, Maillard I, Stanger BZ Intrinsic properties of the lymph node render it immunologically susceptible to metastasis , Cancer Discov, 15(9): 2025,1949-1968

Katsuda T, Sussman JH, Ito K, Katznelson A, Yuan S, Takenaka N, Li J, Merrell AJ, Cure H, Li Q, Rasool RU, Asangani IA, Zaret KS, Stanger BZ Cellular reprogramming in vivo initiated by SOX4 pioneer factor activity , Nat Commun, 15(1): 2024,1761

Kim I-K, Diamond MS, Yuan S, Kemp SB, Kahn BM, Li Q, Lin JH, Li J, Norgard RJ, Thomas SK, Merolle M, Katsuda T, Tobias JW, Baslan T, Politi K, Vonderheide RH, Stanger BZ Plasticity-induced repression of Irf6 underlies acquired resistance to cancer immunotherapy in pancreatic ductal adenocarcinoma , Nat Commun, 15(1): 2024,1532

Kemp SB, Cheng N, Markosyan N, Sor R, Kim I-K, Hallin J, Shoush J, Quinones L, Brown NV, Bassett JB, Joshi N, Yuan S, Smith M, Vostrejs WP, Perez-Vale KZ, Kahn B, Mo F, Donahue TR, Radu CG, Clendenin C, Christensen JG, Vonderheide RH, Stanger BZ Efficacy of a small molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer , Cancer Discov, 13(2): 2023,298-311

Maddipati R, Norgard RJ, Baslan T, Rathi KS, Zhang A, Saeid A, Higashihara T, Wu F, Kumar A, Annamalai V, Bhattacharya S, Raman P, Adkisson CA, Pitarresi JR, Wengyn MD, Yamazoe T, Millstein ID, Bermeo J, Carpenter EL, McAuliffe, Oktay MH, Brekken RA, Lowe SW, lacobuzio-Donahue CA, Notta F, Stanger BZ. MYC levels regulate metastatic heterogeneity in pancreatic adenocarcinoma , Cancer Discov, 12(2): 2022,542-561

Li J, Stanger BZ The tumor as organizer model , Science, 363(6431): 2019,1038-1039

Ben Stanger From One Cell: A Journey into Life's Origins and the Future of Medicine , W.W. Norton: 2023

View all publications